The Takeda-backed gastrointestinal disease therapy developer has boosted its initial public offering to $209m after its shares rose 23% post-flotation.
Gastrointestinal disease drug developer Phathom raised almost $182m in an initial public offering that involved Takeda bumping up its equity stake in the company.
GSK and Merck Group-backed Progyny floated in an offering that involved the fertility benefits manager pricing its shares below their range.
SoftBank Vision Fund-backed immunology therapy developer Vir will float at the bottom of its range, having raised in excess of $820m in VC funding in roughly three years.
The Eli Lilly, Pfizer and Sanofi-backed cancer therapy developer raised $150m despite reducing the number of shares in the IPO and floating beneath its range.
The underwriters for Praktikertjänst-backed Aprea Therapeutics have taken up the over-allotment option in full to boost proceeds to nearly $97.8m.